[Edaily Reporter Park Jeong-soo] #NeoImmuneTech announced on the 10th that it has decided to conduct a 1.5 billion won rights offering to secure operating funds (funds for acquiring all rights to Endari in North America). The capital increase will be conducted via a third-party allotment, with the allottee being Emmaus Life Sciences of the United States. The new shares consist of 683,960 common shares, and the issue price is 2,220 won (discount rate: -10%). The new shares are scheduled to be listed on the 6th of next month.
Disclosure Plus
NeoImmunetech Decides on 1.5 Billion Won Third-Party Allotment Capital Increase
Park Jung-Soo
2026-06-10 16:50:02
Economy
Corporation
IT·Science
Economy
"The Era of AI Diagnosing Diseases"... Medical IP's "Human Digital Twin" Is a Hail-Mary Move
“The next competitive frontier for the medical artificial intelligence (AI) sector does not lie in identifying yet another disease, but rather in how precisely we can understand and digitally replicat…
Corporation
COWAY Expands Nationwide… Opens 10 'COWAY Galleries' in the First Half of This Year
Life solutions company COWAY(021240)announced on the 27th that it opened 10 new “COWAY Gallery” brand experience and retail stores in major commercial districts nationwide during the first half of thi…
IT·Science
The COVID-19 Boom Is Over… What Happened to the Korean Diagnostic Kits That Survived in the U.S.?
The U.S. will end the Emergency Use Authorization (EUA) system for diagnostic kits—which was temporarily permitted during the COVID-19 pandemic—at the end of this year. Going forward, the U.S. COVID-1…
